Results 11 to 20 of about 100,641 (375)

Levodopa versus non-levodopa brain language fMRI in Parkinson’s disease [PDF]

Einstein (São Paulo), 2012
Objective: To identify the effect of levodopa in language areas inParkinson’s disease patients. Methods: We evaluated 50 patientswith mild to moderate Parkinson’s disease, age and gender pairedto 47 healthy volunteers.
Paula Ricci Arantes, Heloise Helena Gobato, Bárbara Bordegatto Davoglio, Maria Ângela Maramaldo Barreiros, André Carvalho Felício, Orlando Graziani Povoas Barsottini, Luiz Augusto Franco de Andrade, Edson Amaro Junior   +7 more
doaj   +3 more sources

The role of gut microbiota tyrosine decarboxylases in levodopa pharmacokinetics: insights from a levodopa challenge test. [PDF]

BMC Neurol
Background The gut microbiota is known to influence levodopa metabolism in the intestinal tract, primarily through the action of tyrosine decarboxylase, an enzyme encoded by the tyrosine decarboxylase gene (tyrDC). However, the effect of the abundance of
Feng Y, Zhang R, Wen G, Xie L, Chen T, Liu W.   +5 more
europepmc   +2 more sources

Levodopa-Induced Changes in Electromyographic Patterns in Patients with Advanced Parkinson’s Disease [PDF]

Frontiers in Neurology, 2018
Levodopa medication is the most efficient treatment for motor symptoms of Parkinson’s disease (PD). Levodopa significantly alleviates rigidity, rest tremor, and bradykinesia in PD.
Verneri Ruonala, Eero Pekkonen, Olavi Airaksinen, Markku Kankaanpää, Pasi A Karjalainen, Saara M Rissanen   +5 more
doaj   +4 more sources

Very-Low-Dose Levodopa Therapy for Pediatric Neurological Disorders: A Preliminary Questionnaire in Japan

Frontiers in Pediatrics, 2021
Introduction: Post-synaptic dopamine receptor supersensitivity (DARSS) has been extensively researched by Dr. Masaya Segawa, who has investigated the efficacy of very-low-dose levodopa therapy (VLDT; 0.5–1 mg/kg/day).
Kyoko Hoshino, Kyoko Hoshino, Kyoko Hoshino, Masaharu Hayashi, Masaharu Hayashi, Masaharu Hayashi, Asayo Ishizaki, Asayo Ishizaki, Kazue Kimura, Kazue Kimura, Masaya Kubota, Masaya Kubota, Atsuo Nezu, Atsuo Nezu, Akihiro Yasuhara, Akihiro Yasuhara   +15 more
doaj   +1 more source

Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals

Movement Disorders, 2023
To compare drug regimens across clinical trials in Parkinson's disease (PD) conversion formulae between antiparkinsonian drugs have been developed.
S. Jost, Marie-Ann Kaldenbach, A. Antonini, P. Martínez-Martín, Lars Timmermann, P. Odin, R. Katzenschlager, R. Borgohain, A. Fasano, F. Stocchi, N. Hattori, P. Kukkle, M. Rodríguez‐Violante, C. Falup-Pecurariu, Sebastian Schade, J. Petry-Schmelzer, V. Metta, D. Weintraub, G. Deuschl, A. Espay, E. Tan, R. Bhidayasiri, Victor S. C. Fung, F. Cardoso, C. Trenkwalder, P. Jenner, K. Ray Chaudhuri, H. Dafsari   +27 more
semanticscholar   +1 more source

Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease

European Journal of Neurology, 2023
Levodopa is the gold standard for the symptomatic treatment of Parkinson's disease (PD). There are well documented motor and non‐motor fluctuations, however, that occur almost inevitably once levodopa is started after a variable period in people with PD.
V. Leta, L. Klingelhoefer, Katherine Longardner, M. Campagnolo, Hafize Çotur Levent, Federico Aureli, V. Metta, R. Bhidayasiri, G. Chung-Faye, C. Falup-Pecurariu, F. Stocchi, P. Jenner, T. Warnecke, K. Ray Chaudhuri   +13 more
semanticscholar   +1 more source

The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program

Frontiers in Neurology, 2022
BackgroundWhile treatment with levodopa remains the cornerstone of Parkinson's disease (PD) management, chronic oral therapy is often associated with the development of motor complications, that correlate to fluctuating levodopa plasma concentrations ...
Peter A. LeWitt, Fabrizio Stocchi, David Arkadir, Yoseph Caraco, Liat Adar, Itay Perlstein, Ryan Case, Nir Giladi   +7 more
doaj   +1 more source

Levodopa-Induced Dyskinesia in Parkinson’s Disease: Pathogenesis and Emerging Treatment Strategies

Cells, 2022
The most commonly used treatment for Parkinson’s disease (PD) is levodopa, prescribed in conjunction with carbidopa. Virtually all patients with PD undergo dopamine replacement therapy using levodopa during the course of the disease’s progression ...
Destany K. Kwon, M. Kwatra, Jing Wang, H. Ko   +3 more
semanticscholar   +1 more source

Levodopa and the dopamine receptor D1-Hippo/yes-associated protein axis: A novel therapeutic avenue for liver fibrosis. [PDF]

World J Gastroenterol
Xie SS, Liu ZG.
europepmc   +2 more sources

Levodopa responsive gait dynamics in OFF- and ONOFF-state freezing of gait in Parkinson’s disease

Clinical Parkinsonism & Related Disorders, 2023
Background: In people with Parkinson’s disease (PwPD), Freezing of Gait (FOG) episodes can be levodopa responsive (OFF-FOG) or levodopa unresponsive (ONOFF-FOG).
Tuhin Virmani, Lakshmi Pillai, Aliyah Glover, Reid D. Landes   +3 more
doaj   +1 more source